

10/597,792mm/dd/yyyy>

=> s l1 sss sam

SAMPLE SEARCH INITIATED 16:27:12 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 35 TO ITERATE

100.0% PROCESSED 35 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 346 TO 1054

PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1


=> d scan

L2 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 3-Piperidinamine, N-[[2,6-dimethoxy-3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methyl]-2-phenyl-, dihydrochloride, (2S,3S)- (9CI)

MF C22 H25 F3 N6 O2 . 2 Cl H

Absolute stereochemistry.



● 2 HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):.


L2 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 3-Piperidinamine, N-[[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methyl]-2-phenyl-, (2R,3R)-

MF C21 H23 F3 N6 O

Absolute stereochemistry.

10/597,792mm/dd/yyyy>



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss full
FULL SEARCH INITIATED 16:27:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 671 TO ITERATE

100.0% PROCESSED 671 ITERATIONS 23 ANSWERS
SEARCH TIME: 00.00.01

L3 23 SEA SSS FUL L1

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	172.55	172.97

FILE 'CAPLUS' ENTERED AT 16:27:58 ON 19 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Dec 2007 VOL 147 ISS 26
FILE LAST UPDATED: 18 Dec 2007 (20071218/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 88 L3

=> s social

17739 SOCIAL

18 SOCIALS

L5 17750 SOCIAL
(SOCIAL OR SOCIALS)

=> s anxiety or anxiolytic or mood or (nervous system) or CNS or stress or emotion?
or phobia

18287 ANXIETY

49 ANXIETIES

18322 ANXIETY
(ANXIETY OR ANXIETIES)

7944 ANXIOLYTIC

9533 ANXIOLYTICS

12667 ANXIOLYTIC
(ANXIOLYTIC OR ANXIOLYTICS)

7647 MOOD

132 MOODS

7715 MOOD
(MOOD OR MOODS)

225409 NERVOUS

2535130 SYSTEM

1392969 SYSTEMS

3441699 SYSTEM
(SYSTEM OR SYSTEMS)

214859 NERVOUS SYSTEM
(NERVOUS (W) SYSTEM)

40622 CNS

560734 STRESS

99033 STRESSES

600258 STRESS
(STRESS OR STRESSES)

11896 EMOTION?

814 PHOBIA

93 PHOBIAS

866 PHOBIA
(PHOBIA OR PHOBIAS)

L6 845313 ANXIETY OR ANXIOLYTIC OR MOOD OR (NERVOUS SYSTEM) OR CNS OR STRE
SS OR EMOTION? OR PHOBIA

=> s 15 or 16

L7 858368 L5 OR L6

=> s 14 and 17

L8 28 L4 AND L7

=> d ti 1-28

L8 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN

TI Melatonin agonist for treatment of depressive disorders

L8 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN

- TI Blockade of tachykinin NK1 receptors attenuates stress-induced rise of extracellular noradrenaline and dopamine in the rat and gerbil medial prefrontal cortex
- L8 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI [3H]GR205171 displays similar NK1 receptor binding profile in gerbil and human brain
- L8 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation
- L8 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI The selective tachykinin neurokinin 1 (NK1) receptor antagonist, GR 205,171, stereospecifically inhibits light-induced phase advances of hamster circadian activity rhythms
- L8 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI [2-methoxy-5-(5-trifluoromethyltetrazol-1-ylbenzyl)]-([2S,3S]-2-phenylpiperidin-3-yl)amine for treatment of posttraumatic stress disorder
- L8 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI Antidepressant-like effects of agomelatine, melatonin and the NK1 receptor antagonist GR205171 in impulsive-related behaviour in rats
- L8 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI Selective and combined neurokinin receptor antagonists
- L8 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI 2-methoxy-5-(5-trifluoromethyltetrazol-1-yl-benzyl)-2S-phenyl-piperidin-3S-yl)-amine for the treatment of social phobia
- L8 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI Cerebral Blood Flow Changes After Treatment of Social Phobia with the Neurokinin-1 Antagonist GR205171, Citalopram, or Placebo
- L8 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI New pharmaceutical combinations of nitric oxide synthase inhibitors and NK-1 receptor antagonists and selective serotonin reuptake inhibitors for treatment of disorders facilitated by altering circadian rhythms
- L8 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI Identification of single-nucleotide polymorphisms of the human neurokinin 1 receptor gene and pharmacological characterization of a Y192H variant
- L8 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI Combination of paroxetine and 2-methoxy-5-(5-trifluoromethyltetrazol-1-ylbenzyl)-(2S-phenylpiperidin-3S-yl)amine for treatment of depression and/or anxiety
- L8 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI Pharmaceutical combinations including either a 5-HT4 receptor agonist or antagonist or a 5-HT3 receptor antagonist and a co-agent and their use in treating gastrointestinal and abdominal visceral disorders

- L8 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI Expression analysis of brain-derived neurotrophic factor (BDNF) mRNA isoforms after chronic and acute antidepressant treatment
- L8 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI Stress-induced increase of cortical dopamine metabolism: attenuation by a tachykinin NK1 receptor antagonist
- L8 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI P-Glycoprotein efflux reduces the brain concentration of the substance P (NK1 receptor) antagonists SR140333 and GR205171: a comparative study using mdrla-/- and mdrla+/+ mice
- L8 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI Distinct effects of diazepam and NK1 receptor antagonists in two conflict procedures in rats
- L8 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI A method for correlating the preprotachykinin gene (NKNA) polymorphisms with the efficacy and compatibility of a pharmaceutically active compounds, such as NK-1 receptor antagonists
- L8 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI Comparison of the functional blockade of rat substance P (NK1) receptors by GR205171, RP67580, SR140333 and NKP-608
- L8 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI Methods using cholinesterase inhibitors for treating and preventing migraine
- L8 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists
- L8 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI Selective, non-peptidergic neurokinin1 receptor antagonists increase extracellular levels of dopamine and noradrenaline in frontal cortex of freely-moving rats
- L8 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI The selective neurokinin (NK)1 antagonist, GR205,171, stereospecifically enhances mesocortical dopaminergic transmission in the rat: a combined dialysis and electrophysiological study
- L8 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI Comparison of the phenotype of NK1R -/- mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs
- L8 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI Substance P receptor antagonist and optional magnesium compound for the treatment of brain, spinal and nerve injury
- L8 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
TI Pharmacological blockade or genetic deletion of substance P (NK1)

receptors attenuates neonatal vocalization in guinea-pigs and mice

L8 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN

TI Alteration of circadian rhythmicity with a tachykinin antagonist

L8 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN

AB The regulation of stress-induced vocalizations by central NK1 receptors was investigated using pharmacol. antagonists in guinea-pigs, a species with human-like NK1 receptors, and transgenic NK1R-/- mice. In guinea-pigs, i.c.v. infusion of the selective substance P agonist GR73632 (0.1 nmol) elicited a pronounced vocalization response that was blocked enantioselectively by the NK1 receptor antagonists CP-99,994 and L-733,060 (0.1-10 mg/kg). GR73632-induced vocalizations were also markedly attenuated by the antidepressant drugs imipramine and fluoxetine (30 mg/kg), but not by the benzodiazepine anxiolytic diazepam (3 mg/kg) or the 5-HT1A agonist buspirone (10 mg/kg). Similarly, vocalizations in guinea-pig pups separated from their mothers were blocked enantioselectively by the highly brain-penetrant NK1 receptor antagonists L-733,060 and GR205171 (ID50 3 mg/kg), but not by the poorly brain-penetrant compds. LY303870 and CGP49823 (30 mg/kg). Separation-induced vocalizations were also blocked by the anxiolytic drugs diazepam, chlordiazepoxide and buspirone (ID50 0.5-1 mg/kg), and by the antidepressant drugs phenelzine, imipramine, fluoxetine and venlafaxine (ID50 3-8 mg/kg). In normal mouse pups, GR205171 attenuated neonatal vocalizations when administered at a high dose (30 mg/kg) only, consistent with its lower affinity for the rat than the guinea-pig NK1 receptor. Ultrasound calls in NK1R-/- mouse pups were markedly reduced compared with those in WT pups, confirming the specific involvement of NK1 receptors in the regulation of vocalization. These observations suggest that centrally-acting NK1 receptor antagonists may have clin. utility in the treatment of a range of anxiety and mood disorders.

ST NK1 receptor antidepressant anxiolytics stress vocalization behavior pig mouse

IT 5-HT agonists

(5-HT1A; substance P (NK1) receptor pharmacol. blockade or genetic deletion attenuates neonatal stress-induced vocalization in guinea-pigs and mice in relation to NK1 antagonist role in treating anxiety and mood disorders)

IT Tachykinin receptors

(NK1 antagonists; substance P (NK1) receptor pharmacol. blockade or genetic deletion attenuates neonatal stress-induced vocalization in guinea-pigs and mice in relation to NK1 antagonist role in treating anxiety and mood disorders)

IT Tachykinin receptors

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(NK1; substance P (NK1) receptor pharmacol. blockade or genetic deletion attenuates neonatal stress-induced vocalization in guinea-pigs and mice in relation to NK1 antagonist role in treating anxiety and mood disorders)

IT Behavior

(locomotor; substance P (NK1) receptor pharmacol. blockade or genetic deletion attenuates neonatal stress-induced vocalization in guinea-pigs and mice in relation to NK1 antagonist role in treating

- anxiety and mood disorders)
- IT Stress, animal
(maternal deprivation; substance P (NK1) receptor pharmacol. blockade or genetic deletion attenuates neonatal stress-induced vocalization in guinea-pigs and mice in relation to NK1 antagonist role in treating anxiety and mood disorders)
- IT Antidepressants
Anxiolytics
Newborn
(substance P (NK1) receptor pharmacol. blockade or genetic deletion attenuates neonatal stress-induced vocalization in guinea-pigs and mice in relation to NK1 antagonist role in treating anxiety and mood disorders)
- IT Behavior
(vocalization; substance P (NK1) receptor pharmacol. blockade or genetic deletion attenuates neonatal stress-induced vocalization in guinea-pigs and mice in relation to NK1 antagonist role in treating anxiety and mood disorders)
- IT 221105-94-8, L 796325
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(L 796325; substance P (NK1) receptor pharmacol. blockade or genetic deletion attenuates neonatal stress-induced vocalization in guinea-pigs and mice in relation to NK1 antagonist role in treating anxiety and mood disorders)
- IT 33507-63-0, Substance P peptide 133156-06-6, GR73632
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(substance P (NK1) receptor pharmacol. blockade or genetic deletion attenuates neonatal stress-induced vocalization in guinea-pigs and mice in relation to NK1 antagonist role in treating anxiety and mood disorders)
- IT 50-49-7, Imipramine 51-71-8, Phenelzine 58-25-3, Chlordiazepoxide 439-14-5, Diazepam 36505-84-7, Buspirone 54910-89-3, Fluoxetine 93413-69-5, Venlafaxine 136982-36-0, Cp-99,994 136982-37-1, CP-100,263 148700-85-0, L-733060 148700-91-8, L-733061 150705-88-7, CGP49823 168266-90-8, GR205171 170566-84-4, LY303870
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substance P (NK1) receptor pharmacol. blockade or genetic deletion attenuates neonatal stress-induced vocalization in guinea-pigs and mice in relation to NK1 antagonist role in treating anxiety and mood disorders)
- L8 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
- IT Stress, animal
(jet lag; tachykinin antagonists for improving the quality of sleep)
- IT 136982-36-0 153438-49-4 155418-05-6 158647-50-8 168266-90-8 170729-80-3 170900-38-6 171242-11-8 172673-20-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tachykinin antagonists for improving the quality of sleep)

```
=> s benzodiazepine or HT1A or antidepressant
    21411 BENZODIAZEPINE
    10795 BENZODIAZEPINES
    24164 BENZODIAZEPINE
          (BENZODIAZEPINE OR BENZODIAZEPINES)
    7975 HT1A
    22104 ANTIDEPRESSANT
    26701 ANTIDEPRESSANTS
    31313 ANTIDEPRESSANT
          (ANTIDEPRESSANT OR ANTIDEPRESSANTS)
L9      60638 BENZODIAZEPINE OR HT1A OR ANTIDEPRESSANT

=> s social (phobia or anxiety)
MISSING OPERATOR 'SOCIAL (PHOBIA'
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s social phobia
    17739 SOCIAL
    18 SOCIALS
    17750 SOCIAL
          (SOCIAL OR SOCIALS)
    814 PHOBIA
    93 PHOBIAS
    866 PHOBIA
          (PHOBIA OR PHOBIAS)
L10     269 SOCIAL PHOBIA
          (SOCIAL(W)PHOBIA)

=> s social anxiety
    17739 SOCIAL
    18 SOCIALS
    17750 SOCIAL
          (SOCIAL OR SOCIALS)
    18287 ANXIETY
    49 ANXIETIES
    18322 ANXIETY
          (ANXIETY OR ANXIETIES)
L11     259 SOCIAL ANXIETY
          (SOCIAL(W)ANXIETY)

=> s l10 or l11
L12     460 L10 OR L11

=> s 19 (L) l12
L13     140 L9 (L) L12

=> s l13.ti
    574 'L13'
    366039 TI
    1277 TIS
    366990 TI
          (TI OR TIS)
L14     0 L13.TI
          ('L13' (W)TI)
```


=> s 113/ti

7817 BENZODIAZEPINE/TI
 3836 BENZODIAZEPINES/TI
 11486 BENZODIAZEPINE/TI
 ((BENZODIAZEPINE OR BENZODIAZEPINES)/TI)
 2916 HT1A/TI
 4935 ANTIDEPRESSANT/TI
 3422 ANTIDEPRESSANTS/TI
 8320 ANTIDEPRESSANT/TI
 ((ANTIDEPRESSANT OR ANTIDEPRESSANTS)/TI)
 4122 SOCIAL/TI
 1 SOCIALS/TI
 4123 SOCIAL/TI
 ((SOCIAL OR SOCIALS)/TI)
 100 PHOBIA/TI
 5 PHOBIAS/TI
 105 PHOBIA/TI
 ((PHOBIA OR PHOBIAS)/TI)
 78 SOCIAL PHOBIA/TI
 ((SOCIAL(W)PHOBIA)/TI)
 4122 SOCIAL/TI
 1 SOCIALS/TI
 4123 SOCIAL/TI
 ((SOCIAL OR SOCIALS)/TI)
 3143 ANXIETY/TI
 3 ANXIETIES/TI
 3146 ANXIETY/TI
 ((ANXIETY OR ANXIETIES)/TI)
 84 SOCIAL ANXIETY/TI
 ((SOCIAL(W)ANXIETY)/TI)
 L15 4 ((BENZODIAZEPINE/TI OR HT1A/TI OR ANTIDEPRESSANT/TI) (L) ((SOCIAL PHOBIA/TI) OR (SOCIAL ANXIETY/TI)))

=> d ti 1-4

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Use of benzodiazepines in social anxiety disorder, generalized anxiety disorder, and posttraumatic stress disorder

 L15 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder)

 L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Treatment of social phobia with antidepressants

 L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
 TI New uses for antidepressants: social phobia

=> d ibib abs 1-4

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:375928 CAPLUS <<LOGINID::20071219>>
 DOCUMENT NUMBER: 141:16718

TITLE: Use of benzodiazepines in social anxiety disorder, generalized anxiety disorder, and posttraumatic stress disorder

AUTHOR(S): Davidson, Jonathan R. T.

CORPORATE SOURCE: Department of Psychiatry and Behavioral Sciences, Duke University Medical Center South, Durham, NC, USA

SOURCE: Journal of Clinical Psychiatry (2004), 65(Suppl. 5), 29-33

CODEN: JCLPDE; ISSN: 0160-6689

PUBLISHER: Physicians Postgraduate Press, Inc.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Benzodiazepines are advantageous treatments for anxiety disorders because they work quickly. However, benzodiazepines can vary in terms of efficacy across anxiety disorders. Benzodiazepines have been found to be a superior treatment in social anxiety disorder. While benzodiazepines are effective in the treatment of generalized anxiety disorder, other treatments such as selective serotonin reuptake inhibitors may be more effective. Also, research indicates that benzodiazepines may not be effective in the treatment of posttraumatic stress disorder. Therefore, physicians need to consider the type of anxiety disorder before prescribing a benzodiazepine as a treatment.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:120960 CAPLUS <<LOGINID::20071219>>

DOCUMENT NUMBER: 135:146524

TITLE: Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder)

AUTHOR(S): Jefferson, James W.

CORPORATE SOURCE: University of Wisconsin Medical School, Madison, WI, 53717, USA

SOURCE: Journal of Clinical Psychiatry (2001), 62(Suppl. 1), 50-53

CODEN: JCLPDE; ISSN: 0160-6689

PUBLISHER: Physicians Postgraduate Press, Inc.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review with 22 refs. Both benzodiazepines and conventional anticonvulsants have been evaluated as treatments for social phobia (social anxiety disorder). Among the benzodiazepines, clonazepam is the best studied, although there is reason to expect that all benzodiazepine anxiolytics would be effective for this condition. Among the anticonvulsants, gabapentin and pregabalin, an analog of γ -aminobutyric acid (GABA), have been shown to be more effective than placebo in double-blind studies. Other than a small neg. open study of valproic acid for social phobia, there is a paucity of information on whether other anticonvulsants might be useful for this condition.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:120959 CAPLUS <<LOGINID::20071219>>

DOCUMENT NUMBER: 135:146523

TITLE: Treatment of social phobia with antidepressants
 AUTHOR(S): Schneier, Franklin R.
 CORPORATE SOURCE: Anxiety Disorders Clinic, New York State Psychiatric Institute and the College of Physicians, Surgeons of Columbia University, New York, NY, 10032, USA
 SOURCE: Journal of Clinical Psychiatry (2001), 62(Suppl. 1), 43-49
 CODEN: JCLPDE; ISSN: 0160-6689
 PUBLISHER: Physicians Postgraduate Press, Inc.
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review with 39 refs. This article reviews evidence for the utility of antidepressant medications in the treatment of social phobia. Monoamine oxidase inhibitors (MAOIs) were the first antidepressants shown to be effective for social phobia, but dietary restrictions and a relatively high rate of adverse effects often relegate MAOIs to use after other treatments have been found ineffective. Reversible inhibitors of monoamine oxidase (RIMAs) hold promise as safer alternatives to MAOIs, but RIMAs may be less effective and are currently unavailable in the United States. Selective serotonin reuptake inhibitors (SSRIs), of which paroxetine has been the best studied in social phobia to date, have recently emerged as a first-line treatment for the generalized subtype of social phobia. The SSRIs are well tolerated and consistently have been shown to be efficacious in controlled trials.
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:20687 CAPLUS <<LOGINID::20071219>>
 DOCUMENT NUMBER: 128:162437
 TITLE: New uses for antidepressants: social phobia
 AUTHOR(S): Keck, Paul E., Jr.; Mcelroy, Susan L.
 CORPORATE SOURCE: Department of Psychiatry, Biological Psychiatry Program University of Cincinnati College of Medicine, Cincinnati, OH, 45267-0559, USA
 SOURCE: Journal of Clinical Psychiatry (1997), 58(Suppl. 14), 32-38
 CODEN: JCLPDE; ISSN: 0160-6689
 PUBLISHER: Physicians Postgraduate Press
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review with 50 refs. Data from recent epidemiol. surveys of community populations indicate that social phobia is a common psychiatric disorder and is associated with substantial functional impairment in a number of patients. Social phobia is also often comorbid with major depression, substance use disorders, and other anxiety disorders. Fortunately, a variety of antidepressant medications have been reported to alleviate the symptoms of social phobia. Controlled studies have shown substantial efficacy for the monoamine oxidase inhibitors phenelzine, moclobemide, and brofaromine and the serotonin selective reuptake inhibitors fluvoxamine and sertraline. Other serotonin reuptake inhibitors and venlafaxine have shown promise in case reports and open trials.
 REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/597,792mm/dd/yyyy>